International Companies

AbbVie to buy biotech firm Apogee Therapeutics for $10.9bn

By Michele Maatouk

Date: Monday 22 Jun 2026

(Sharecast News) - AbbVie said on Monday that it has agreed to buy clinical-stage biotechnology company Apogee Therapeutics for $10.9bn.
Under the terms of the deal, which is expected to close in the third quarter, AbbVie will pay $135.11 per share in cash.

AbbVie said the acquisition complements its existing...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page